TABLE 4.
Historical Controls of R+ LTR Receiving High‐Dose VGCV Prophylaxis
| Study | Sample | Maintenance Immunosuppression | Prophylactic Regimen | CMV Disease Incidence, n (%) | CMV Disease Type | P Value* |
|---|---|---|---|---|---|---|
| Lindner et al. 12 (2016) | 21 D+R+ | Glucocorticoids, tacrolimus, MMF | VGCV 900 mg/day for 100 days | 1 (5) | Tissue‐invasive | 1.00 |
| Fayek et al. 13 (2010) | 109 non‐D+R− | Prednisone, tacrolimus or cyclosporine, MMF | VGCV 900 mg/day (n = 61) or oral GCV 1 g tid (n = 48) for 90 days | 5 (5)‡ | CMV syndrome (n = 4); tissue‐invasive (n = 1) | 0.97 |
| Limaye et al. 14 (2006) | 294 R+ | Prednisone, tacrolimus or cyclosporine A, azathioprine or MMF | VGCV 900 mg/day or oral GCV 1 g tid for 90 days | 14 (5)‡ | CMV syndrome (n = 9); tissue‐invasive (n = 5) | 0.89 |
| Jain et al. 15 (2005) | 114 R+ | Steroids, tacrolimus, MMF | VGCV 900 mg/day or 450 mg every other day depending on renal function for 90‐180 days | 15 (13) | “Symptomatic” nontissue invasive (n = 13); tissue‐invasive (n = 2) | 0.005 |
Reproduced with permission from Liver Transplantation. 10 Copyright 2018, American Association for the Study of Liver Diseases.
*
Probability of CMV disease compared with our cohort using Fisher’s exact test or Pearson chi‐square test as appropriate.
‡
Not specified which patients received VGCV versus GCV; no significant difference in CMV disease incidence between VGCV and GCV groups.